

Special Issue

Combination Therapy for Hepatocellular Carcinoma

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Despite advances in diagnosis and treatment, the prognosis for HCC patients remains unsatisfactory, with limited curative options available. Combination therapy, involving the use of multiple treatment modalities simultaneously or sequentially, has emerged as a promising strategy to improve patient outcomes. These may include surgical interventions, tumor ablation, transarterial chemoembolization (TACE), transarterial chemoinfusion (HAIC), radiation therapy, systemic therapies and others. In this Special Issue, we will address the challenges and future directions of combination therapy for HCC. These may encompass novel combination strategies and potential synergies, with emerging therapies such as molecular targeted agents and immune checkpoint inhibitors. The goal of this Special Issue is to gather a comprehensive collection of articles that explore the various aspects of combination therapy for HCC, by reviewing the latest research, clinical trials and expert opinions.

Guest Editor

Dr. Toshihiro Tanaka

Department of Diagnostic and Interventional Radiology, Nara Medical University, Shijyocho 840, Kashihara City 634-8522, Japan

Deadline for manuscript submissions

closed (29 February 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/178661

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)